glp 1 receptor agonists list Market Overview: GLP-1 and the Obesity Market | Blog Glp 1 Receptor Agonists List
Description
It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.

Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity

Semaglutide and tirzepatide for visceral fat and the thin-fat phenotype

Preclinical studies suggest that GIPR antagonism helps with weight loss and metabolic improvements

Nevertheless, the overall drug exposure was not considered clinically significant

Once Monthly GLP-1 Maridebart cafraglutide is an investigational once-monthly injectable drug developed by Amgen that shows significant promise for treating obesity and Type 2 diabetes
